If you need to screen dozens of genetic loci for copy number changes without investing in a full microarray workflow, MLPA offers a precise, multiplexed solution. Multiplex Ligation-Dependent Probe Amplification (MLPA) is a targeted technique that enzymatically covalently joins a pair of probes for each genomic target, then amplifies all ligated probes simultaneously with a single universal primer pair. The resulting amplicons are separated by size via capillary electrophoresis and quantified relative to reference samples, enabling accurate detection of gene deletions and duplications across 5 to 50 loci in one tube.
MLPA turns a complex CNV detection problem into a streamlined, low-cost assay by eliminating differential PCR bias through universal priming and by using stuffer-length differences to enable single-capillary readout. This makes it a go‑to choice for diagnostic developers who need high‑throughput, exon‑level dosage screening without the infrastructure or cost of array‑based methods.
The MLPA Workflow: Step-by-Step
The power of MLPA rests on three tightly integrated steps that convert sequence‑specific hybridization into quantifiable, size‑resolved amplicons.
Dual‑Probe Hybridization and Ligation
For each target locus, two oligonucleotide probes are designed to hybridize immediately adjacent to one another on the sample DNA.
Each probe has a target‑specific arm and a unique, non‑hybridizing tail that contains a universal priming site and a variable‑length stuffer sequence.
Only when both probes bind perfectly side by side does DNA ligase form a covalent bond between them. This ligation event is the critical specificity gate—mismatched or missing targets yield no amplifiable template.
Universal PCR Amplification
Once ligated, all probe pairs become templates that share identical universal primer sites at their ends.
A single pair of fluorescently labeled primers amplifies every ligated product in the same reaction tube. This universal priming strategy completely bypasses the differential amplification bias that plagues traditional multiplex PCR, where different primer sets can perform with wildly different efficiencies.
Because every amplicon is generated by the same primer pair, the relative amount of each PCR product faithfully reflects the original copy number of the target sequence in the sample.
Capillary Electrophoresis and Relative Quantification
Each probe pair incorporates a unique stuffer length—a non‑coding tail of a specific number of nucleotides—so every target produces an amplicon of a distinct size.
After PCR, the mix is run on a capillary electrophoresis instrument. The instrument separates the fragments by length and measures the fluorescent peak area (or height) for each.
Copy number is determined by comparing the peak area of a test sample to that of a reference sample (or to internal control probes) for each locus. A peak ratio of ~0.5 indicates a heterozygous deletion, ~1.5 a heterozygous duplication, and ~1.0 a normal diploid copy number.
Why MLPA Excels in Diagnostic CNV Analysis
MLPA’s design naturally aligns with the demands of clinical diagnostics for gene dosage assessment.
High Multiplexing, Targeted Resolution
MLPA typically evaluates 5 to 50 specific loci in a single reaction. This sweet spot allows comprehensive screening of all exons in a gene of interest (e.g., DMD, BRCA1) or a focused panel of disease‑relevant genes.
Unlike genome‑wide arrays, MLPA does not generate vast amounts of incidental data, which simplifies interpretation and reduces the need for advanced bioinformatics infrastructure.
Inherent Bias Elimination
The single universal primer pair ensures uniform amplification efficiency across all targets. Traditional multiplex PCR requires careful balancing of multiple primer concentrations and thermal profiles; MLPA sidesteps that entirely.
This uniformity makes the relative quantification far more robust and reproducible, a non‑negotiable requirement for diagnostic‑grade copy number calls.
Cost-Effectiveness and Accessibility
MLPA requires only standard laboratory equipment—a thermocycler and a capillary electrophoresis instrument—both of which are common in diagnostic labs. There is no need for costly microarray scanners or high‑throughput sequencing infrastructure.
Ready‑to‑use MLPA probe mixes and reagent kits are commercially available for many established diagnostic applications, further lowering development and validation barriers for the end user.
Understanding the Trade-offs and Limitations
No technique is perfect, and an informed choice requires acknowledging where MLPA reaches its edges.
Demanding Probe Design and Synthesis
Each target requires two high‑purity oligonucleotides with carefully tuned melting temperatures and stuffer‑tail lengths so that all amplicons resolve cleanly on the capillary. Poor design can lead to probe cross‑reactivity or overlapping peaks.
Synthesizing probes with custom mobility tails is a specialized task, and any lot‑to‑lot variability can affect the assay’s baseline performance.
Relative Quantification Demands Normalization
MLPA provides only relative copy numbers, not absolute molecule counts. Accurate calls rely on well‑characterized reference samples run in the same batch and often on internal control probes to normalize for sample input and DNA quality.
This means that every run must include appropriate controls, and the assay is sensitive to sample degradation that can cause uneven amplification of different‑length amplicons.
Narrow Variant Scope
MLPA detects copy number variations—deletions and duplications—but is blind to balanced translocations, inversions, and the vast majority of point mutations. It also cannot differentiate between a duplication and a triplication unless intentionally designed probes are added.
The practical limit of ~50 targets means it is not suitable for genome‑wide discovery; it is a hypothesis‑driven, targeted tool.
Making the Right Choice for Your Diagnostic Goal
Your decision to adopt MLPA should hinge on the scale and nature of your CNV detection needs.
- If your primary focus is targeted, exon‑level CNV screening in a defined set of 20–50 genes: MLPA provides a highly multiplexed yet straightforward workflow that avoids the cost and complexity of array CGH or next‑generation sequencing CNV pipelines.
- If your primary focus is single‑gene dosage analysis using validated kits (e.g., for DMD, BRCA1, or SMA): MLPA offers a proven, CE‑IVD‑marketed solution with established interpretive guidelines, simplifying regulatory approval and lab implementation.
- If your primary focus is minimizing capital expenditure in a resource‑constrained diagnostic setting: MLPA’s reliance on a standard thermocycler and capillary electrophoresis keeps equipment costs low while still delivering robust, relative quantification data.
When your goal is precise, multiplexed gene copy number assessment without the overhead of larger discovery platforms, MLPA strikes a uniquely practical balance between throughput, reliability, and cost.
Summary Table:
| Workflow Step / Feature | Mechanism & Key Details | Clinical Advantage |
|---|---|---|
| Probe Hybridization & Ligation | Two adjacent target probes covalently joined by DNA ligase | High specificity; zero amplification of non-ligated probes |
| Universal PCR Amplification | Single fluorescent primer pair amplifies all probe targets | Eliminates differential amplification bias for uniform results |
| Capillary Electrophoresis | Size-based separation via target-specific stuffer sequences | Enables precise single-tube quantification of 5–50 loci |
| Cost & Infrastructure | Requires standard thermocyclers and capillary electrophoresis | Highly cost-effective without array or NGS overhead |
Developing targeted CNV assays or looking to optimize your diagnostic molecular workflows? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and specialized consulting—supporting your team through every stage from concept to clinic. Contact us today to accelerate your diagnostic assay development!